Litcius/Paper detail

Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks

Amirah E.-E. Aly, Nicholas S. Caron, Hailey Findlay Black, Mandi E. Schmidt, Christine Anderson, Seung‐Hyun Ko, Helen J. E. Baddeley, Lisa M. Anderson, Lorenzo Casal, Reza S.M. Rahavi, Dale D. O. Martin, Michael R. Hayden

2023Journal of Controlled Release15 citationsDOIOpen Access PDF

Abstract

Lowering mutant huntingtin (mHTT) in the central nervous system (CNS) using antisense oligonucleotides (ASOs) is a promising approach currently being evaluated in clinical trials for Huntington disease (HD). However, the therapeutic potential of ASOs in HD patients is limited by their inability to cross the blood-brain barrier (BBB). In non-human primates, intrathecal infusion of ASOs results in limited brain distribution, with higher ASO concentrations in superficial regions and lower concentrations in deeper regions, such as the basal ganglia. To address the need for improved delivery of ASOs to the brain, we are evaluating the therapeutic potential of apolipoprotein A-I nanodisks (apoA-I NDs) as novel delivery vehicles for mHTT-lowering ASOs to the CNS after intranasal administration. Here, we have demonstrated the ability of apoA-I nanodisks to bypass the BBB after intranasal delivery in the BACHD model of HD. Following intranasal administration of apoA-I NDs, apoA-I protein levels were elevated along the rostral-caudal brain axis, with highest levels in the most rostral brain regions including the olfactory bulb and frontal cortex. Double-label immunohistochemistry indicates that both the apoA-I and ASO deposit in neurons. Most importantly, a single intranasal dose of apoA-I ASO-NDs significantly reduces mHTT levels in the brain regions most affected in HD, namely the cortex and striatum. This approach represents a novel non-invasive means for improving delivery and brain distribution of oligonucleotide therapies and enhancing likelihood of efficacy. Improved ASO delivery to the brain has widespread application for treatment of many other CNS disorders.

Topics & Concepts

Nasal administrationHuntingtinStriatumOlfactory bulbPharmacologyCentral nervous systemMedicineBasal gangliaHuntington's diseaseNeuroscienceBiologyPathologyInternal medicineDiseaseDopamineGenetic Neurodegenerative DiseasesNeurological disorders and treatmentsRNA Research and Splicing
Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks | Litcius